You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
|
|---|---|
| Published in |
BMC Cancer, November 2015
|
| DOI | 10.1186/s12885-015-1894-5 |
| Pubmed ID | |
| Authors |
Mathilde Penel-Page, Isabelle Ray-Coquard, Julie Larcade, Magali Girodet, Laure Bouclier, Muriel Rogasik, Nadège Corradini, Natacha Entz-Werle, Laurence Brugieres, Julien Domont, Cyril Lervat, Sophie Piperno-Neumann, Helène Pacquement, Jacques-Olivier Bay, Jean-Claude Gentet, Antoine Thyss, Loic Chaigneau, Bérangère Narciso, Helène Cornille, Jean-Yves Blay, Perrine Marec-Bérard |
| Abstract |
The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) national registry. All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed. Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The median age at the beginning of treatment was 19 years (range 9-72). The median number of previous lines of chemotherapy was 3 (range 1-8). Before inclusion, 3 patients were in second complete remission, 26 were in progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5 % of patients (95 % Confidence Interval (CI) [20-52.8]). The median Progression-Free Survival (PFS) was 3 months (95 % CI [2-5.4]) for patients treated by sirolimus and 1.8 months (95 % CI [1.3-2.8]) for patients receiving multi-targeted tyrosine kinase inhibitors; 6-month PFS 15 %. The median Overall Survival (OS) was 6.8 months (95 % CI [4.7-12.1]), and one-year OS was 24 %. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to other TTs (Hazard Ratio (HR) = 2.7, 95 % CI [1.05-7.1]). No toxic death was reported. Grade 3 and 4 toxicities were observed in 27 and 6 % of cases respectively. Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with an acceptable toxicity profile, including in pediatric population. |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 20% |
| Researcher | 9 | 20% |
| Student > Master | 4 | 9% |
| Student > Ph. D. Student | 3 | 7% |
| Student > Postgraduate | 3 | 7% |
| Other | 8 | 17% |
| Unknown | 10 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Agricultural and Biological Sciences | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Business, Management and Accounting | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 11 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2016.
All research outputs
#15,349,796
of 22,832,057 outputs
Outputs from BMC Cancer
#4,113
of 8,306 outputs
Outputs of similar age
#166,996
of 285,414 outputs
Outputs of similar age from BMC Cancer
#110
of 248 outputs
Altmetric has tracked 22,832,057 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,306 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,414 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 248 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.